# Staar Surgical Co: Form 10-Q for the period ended Oct 2, 2020

- Company: [Staar Surgical Co](/companies/staa.md) (CIK 718937)
- Form: 10-Q
- Filed: 2020-11-04
- Accepted by EDGAR: Nov 4, 2020, 16:10 ET
- Period: 2020-10-02
- Accession: 0001564590-20-050470
- Inline XBRL: yes
- Main document: https://www.sec.gov/Archives/edgar/data/718937/000156459020050470/staa-10q_20201002.htm
- All documents and exhibits: https://www.sec.gov/Archives/edgar/data/718937/000156459020050470/

## Figures reported in this filing

Standardized XBRL line items for the period ended 2020-10-02.

| Line item | Period | Value | XBRL concept |
| --- | --- | ---: | --- |
| Revenue | 3 months, 2020-07-04 to 2020-10-02 | $5.6m | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Revenue | 9 months, 2020-01-04 to 2020-10-02 | $15.9m | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Cost of revenue | 3 months, 2020-07-04 to 2020-10-02 | $12.2m | us-gaap:CostOfGoodsAndServicesSold |
| Cost of revenue | 9 months, 2020-01-04 to 2020-10-02 | $33.4m | us-gaap:CostOfGoodsAndServicesSold |
| Gross profit | 3 months, 2020-07-04 to 2020-10-02 | $34.9m | us-gaap:GrossProfit |
| Gross profit | 9 months, 2020-01-04 to 2020-10-02 | $84.1m | us-gaap:GrossProfit |
| Research and development | 3 months, 2020-07-04 to 2020-10-02 | $8.8m | us-gaap:ResearchAndDevelopmentExpense |
| Research and development | 9 months, 2020-01-04 to 2020-10-02 | $23.0m | us-gaap:ResearchAndDevelopmentExpense |
| Selling, general and administrative | 3 months, 2020-07-04 to 2020-10-02 | $30.0m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Selling, general and administrative | 9 months, 2020-01-04 to 2020-10-02 | $81.4m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Operating income | 3 months, 2020-07-04 to 2020-10-02 | $4.9m | us-gaap:OperatingIncomeLoss |
| Operating income | 9 months, 2020-01-04 to 2020-10-02 | $2.7m | us-gaap:OperatingIncomeLoss |
| Income tax | 3 months, 2020-07-04 to 2020-10-02 | $1.5m | us-gaap:IncomeTaxExpenseBenefit |
| Income tax | 9 months, 2020-01-04 to 2020-10-02 | $887.0k | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months, 2020-07-04 to 2020-10-02 | $3.9m | us-gaap:NetIncomeLoss |
| Net income | 9 months, 2020-01-04 to 2020-10-02 | $2.6m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months, 2020-07-04 to 2020-10-02 | $0.08 | us-gaap:EarningsPerShareDiluted |
| Diluted EPS | 9 months, 2020-01-04 to 2020-10-02 | $0.05 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months, 2020-07-04 to 2020-10-02 | $0.08 | us-gaap:EarningsPerShareBasic |
| Basic EPS | 9 months, 2020-01-04 to 2020-10-02 | $0.06 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months, 2020-07-04 to 2020-10-02 | 48,180,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Diluted shares (weighted) | 9 months, 2020-01-04 to 2020-10-02 | 47,589,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 9 months, 2020-01-04 to 2020-10-02 | $1.4m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 9 months, 2020-01-04 to 2020-10-02 | $6.3m | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Cash and equivalents | at 2020-10-02 | $128.3m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | at 2020-10-02 | $196.0m | us-gaap:AssetsCurrent |
| Total assets | at 2020-10-02 | $234.7m | us-gaap:Assets |
| Current liabilities | at 2020-10-02 | $33.9m | us-gaap:LiabilitiesCurrent |
| Total liabilities | at 2020-10-02 | $48.3m | us-gaap:Liabilities |
| Shareholders' equity | at 2020-10-02 | $186.4m | us-gaap:StockholdersEquity |

## Sections

The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. https://www.sec.gov/Archives/edgar/data/718937/000156459020050470/staa-10q_20201002.htm

Filed Nov 4, 2020.
Source: SEC EDGAR, the filing index for accession 0001564590-20-050470. Last ingested by Listed: Nov 4, 2026, 17:00 ET. No prices; not investment advice.
